University of Kansas Alzheimer's Disease Research Center (KU ADRC)

堪萨斯大学阿尔茨海默病研究中心 (KU ADRC)

• 批准号: 10666543
• 负责人: RUSSELL H. SWERDLOW
• 金额: $ 304.26万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10666543
• 关键词: Address; Affect; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Area; Automobile Driving; Back; Bioenergetics; Biological Markers; Brain; Caring; Cells; Center Core Grants; Clinic; Clinical; Clinical Trials; Collaborations; Development; Dryness; Education; Energy Metabolism; Functional disorder; Funding; Genes; Genetic; Goals; Grant; Infrastructure; International; Intervention; Intervention Studies; Investments; Kansas; Knowledge; Life Style; Life Style Modification; Link; Metabolism; Mitochondria; Mitochondrial Diseases; Persons; Play; Prevention; Prevention Research; Process; Proteins; Publications; Research; Research Personnel; Research Project Grants; Resources; Role; Science; Symptoms; Testing; Therapeutic; Therapeutic Intervention; Universities; Work; aging brain; clinical care; clinical implementation; clinical practice; empowerment; health care delivery; implementation science; innovation; lifestyle intervention; metabolic abnormality assessment; novel; pharmacologic; programs; protein aggregation; proteostasis; success; targeted treatment

ABSTRACT: OVERALL The University of Kansas Alzheimer's Disease Research Center (KU ADRC) promotes Alzheimer's Disease and Related Disorders (ADRD) research at local, national, and international levels. Our strengths in basic and translational mitochondria, lifestyle modification, and prevention research define a metabolism theme we pursued and refined over the past decade. We boast a sophisticated and mature infrastructure that advances a better understanding of AD, better care of affected persons, and new treatment interventions. The KU ADRC will use its intellectual and infrastructure assets this next cycle to drive AD research at a university vested and investing in our success, and in doing so move the field closer to a cure. Our Center moves seamlessly between bench and bedside, both in terms of the research projects we support, and in the infrastructure required to back investigator projects. Lifestyle intervention research generates fundamental mechanistic questions we call on wet lab investigators to address, and questions of clinical implementation and practice are now the focus of dry lab, clinical, and health care delivery investigators. Research addressing AD's mitochondrial component demonstrate a role for mitochondrial genes in AD risk, that mitochondria play a critical role in cell proteostasis and protein aggregation, specific links between mitochondria and AD hallmark proteins, and how to manipulate brain energy metabolism through lifestyle and pharmacologic approaches. To date these efforts led us to create novel compounds that constitute a unique therapeutic pipeline, and clinical trial infrastructure that supports actual studies of metabolism interventions in actual AD patients. For the 2021-26 cycle we will use our intellectual and infrastructure assets to address critical gaps in the AD field, including gaps in fundamental knowledge and care implementation. During this cycle the KU ADRC will work to (1) Empower innovative AD and brain aging research, education, and clinical programs; (2) Drive field-defining metabolism research, and (3) Bring practical and novel metabolism-directed therapies to the bedside and clinic.

摘要：总体 堪萨斯大学阿尔茨海默病研究中心（KU ADRC）促进阿尔茨海默病 疾病和相关疾病（ADRD）研究在地方，国家和国际层面。我们的优势在于 基本和翻译线粒体，生活方式的改变，和预防研究确定了代谢的主题 我们在过去十年中追求和完善的。我们拥有先进成熟的基础设施， 促进了对AD的更好理解，更好地照顾受影响的人，以及新的治疗干预措施。的 KU ADRC将在下一个周期利用其知识和基础设施资产推动大学的AD研究 投资于我们的成功，并在这样做的过程中使该领域更接近治愈。 我们的中心在长凳和床边之间无缝移动，无论是在我们的研究项目方面， 支持，以及支持调查项目所需的基础设施。生活方式干预研究 产生了我们要求湿实验室研究人员解决的基本机械问题， 临床实施和实践现在是干实验室、临床和卫生保健交付的重点 investigators.针对AD线粒体成分的研究证明了线粒体基因的作用 在AD风险中，线粒体在细胞蛋白质稳态和蛋白质聚集中起关键作用， 线粒体和AD标志蛋白之间的关系，以及如何通过 生活方式和药理学方法。到目前为止，这些努力使我们创造了新的化合物， 独特的治疗管道和临床试验基础设施，支持代谢的实际研究 对实际AD患者的干预。 在2021- 2026年周期，我们将利用我们的知识和基础设施资产来解决 AD领域，包括基础知识和护理实施方面的差距。在这个周期中，KU ADRC 将致力于（1）授权创新的AD和脑老化研究，教育和临床计划;（2）推动 领域定义的代谢研究，（3）带来实用和新颖的代谢导向疗法， 床旁和诊所。